Our commitment to our communities

The health and safety of our patients is and always will be our highest priority. We understand those living with multiple sclerosis (MS) and their loved ones may be facing a lot of uncertainty during this serious health situation, and we are committed to keeping the communities we serve updated with any information that could help inform health decisions related to our medicines.

COVID-19 is caused by a new strain of coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), so knowledge about how it may affect people with MS and those treated with OCREVUS is currently unavailable. Therefore, we do not yet have data to inform specific recommendations or changes to treatment with OCREVUS. We are actively discussing with the neurology community to gain insights and perspectives. Please speak with your doctor or healthcare team before stopping or delaying treatment, as we believe that treatment decisions are personal and should be made between you and your healthcare team. Your doctor will be able to assess the benefits and risks specific to your overall health situation. If you have experienced a change in insurance or income, or if you are looking for support in finding infusion site options for your next OCREVUS treatment, including home infusion, please call OCREVUS CONNECTS at 1-844-OCREVUS (1-844-627-3887) to speak with a Patient Navigator or representative.

MS is thought to affect both the central nervous system and immune system, and OCREVUS was designed to target certain types of B cells. Those receiving OCREVUS may have an increased risk of getting certain infections, including upper respiratory tract infections. In patients with active infections, including COVID-19, treatment with OCREVUS should be delayed until the infection is gone. Patients receiving OCREVUS who are either exposed to the coronavirus or confirmed to have the COVID-19 infection should contact their doctor or other medical professional right away.

In addition to local public health guidance, or local guidance specifically issued by medical or patient associations, please find more information on Genentech’s response to the COVID-19 pandemic and other support services on the Genentech website.